Payment overview · 2025
General Payments
$1,369.94
58 reported records · 17 companies
Healthcare provider profile · identity verified
Jin Yi Kim
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BRONX, NY · NPI 1659801132
Verified facts
What the public records show
CMS Open Payments records show Jin Yi Kim received $1,369.94 in general payments during 2025 across 58 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $287.42 | 21.0% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $223.47 | 16.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $184.74 | 13.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $131.88 | 9.6% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $105.56 | 7.7% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $89.53 | 6.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.54 | 6.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.61 | 4.3% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.18 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.01 | 2.9% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.10 | 1.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.85 | 1.4% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $19.48 | 1.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.97 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.64 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.24 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.72 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,270.94 | 57 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $184.74 | 10 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $168.15 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $124.47 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $119.27 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $105.56 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $89.53 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.35 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.54 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.54 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 121 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 265 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
121 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
265 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
195 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
131 | 18 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 843 | 177 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 683 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 461 | 99 |
| Metformin Hcl | Metformin Hcl | 444 | 90 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 328 | 77 |
| Omeprazole | Omeprazole | 318 | 63 |
| Montelukast Sodium | Montelukast Sodium | 316 | 60 |
| Lisinopril | Lisinopril | 298 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 288 | 81 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 265 | 40 |
| Famotidine | Famotidine | 253 | 48 |
| Diclofenac Sodium Er | Diclofenac Sodium | 210 | 13 |
| Jardiance | Empagliflozin | 195 | 39 |
| Doxepin Hcl | Doxepin Hcl | 190 | 17 |
| Gabapentin | Gabapentin | 180 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 45 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 177 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 33 |
| Ozempic | Semaglutide | 149 | 24 |
| Losartan Potassium | Losartan Potassium | 148 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 25 |
| Alendronate Sodium | Alendronate Sodium | 131 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 34 |
| Trulicity | Dulaglutide | 131 | 18 |
| Januvia | Sitagliptin Phosphate | 129 | 21 |
| Farxiga | Dapagliflozin Propanediol | 121 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 32 |
| Ezetimibe | Ezetimibe | 112 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 33 |
| Glipizide Er | Glipizide | 91 | 18 |
| Meloxicam | Meloxicam | 85 | 35 |
| Single Use Swab | Alcohol Antiseptic Pads | 84 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 78 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 77 | 16 |
| Simvastatin | Simvastatin | 75 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 17 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 73 | 16 |
| Carvedilol | Carvedilol | 72 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 69 | 14 |
| Nifedipine Er | Nifedipine | 67 | 15 |
| Ammonium Lactate | Ammonium Lactate | 66 | 20 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 64 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 12 |
| Naproxen | Naproxen | 46 | 18 |
| Trazodone Hcl | Trazodone Hcl | 43 | 13 |
| Furosemide | Furosemide | 42 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Eliquis | Apixaban | 40 | 11 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 20 |
| Ibuprofen | Ibuprofen | 37 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 11 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 12 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Etodolac | Etodolac | 24 | 12 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Budesonide Er | Budesonide | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 20 |
| Topiramate | Topiramate | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 12 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Steglatro | Ertugliflozin Pidolate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,369.94 · 58 records | Teva Pharmaceuticals USA, Inc. | ACCRUFER, AIRSUPRA, AUSTEDO XR, BREZTRI, Bimzelx, Cologuard Collection Kit, ENTRESTO, FARXIGA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QUTENZA, REPATHA, REXULTI, Symbravo, TRELEGY ELLIPTA, UZEDY, Veozah, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error